NCT00944541View on ClinicalTrials.gov

Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

January 31, 2011

Conditions
HIV InfectionHIV Infections
Interventions
DRUG

maraviroc

maraviroc 150 mg or 300 mg or 600 mg twice a day for 24 weeks

Trial Locations (1)

75013

French National Agency for Research on AIDS and Viral Hepatits, Paris

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

French National Agency for Research on AIDS and Viral Hepatitis

OTHER_GOV

NCT00944541 - Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration | Biotech Hunter | Biotech Hunter